Sunday 18 October 2026
Export XAIR’s income statement to Excel — free account
Beyond Air, Inc.
XAIR Healthcare Medical Devices
Beyond Air, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $7.7 million, up 107.3% from fiscal 2025. In the quarter to June 2026, revenue was flat, EPS grew 64.1%, free cash flow fell 9.10% and total debt rose 127.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
2.16
0.05
−2.26%
Follow XAIR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.53 | 0.90 | 0.75 | 0.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.30) | (1.48) | (1.16) | (1.30) | |
P/B ratio |
1.12 | 0.76 | 0.92 | 2.27 | |
Price to Tangible BV |
1.23 | 0.87 | 1.10 | 3.44 | |
EV/Sales |
2.44 | 1.53 | 1.37 | 1.77 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.60) | (0.53) | (0.58) | (0.73) | |
EV/FCF |
(0.54) | (0.48) | (0.55) | (0.69) | |
Quick Ratio |
2.68 | 3.81 | 2.82 | 2.37 | |
Current Ratio |
4.24 | 5.12 | 3.80 | 3.31 | |
Net Debt/EBITDA |
0.12 | (0.74) | (0.78) | (1.35) | |
Debt/Assets |
32.57% | 59.75% | 62.29% | 68.10% | |
Debt/Equity |
0.77 | 2.65 | 3.55 | 7.89 | |
Asset Turnover |
0.14 | 0.20 | 0.23 | 0.25 | |
Operating CF/Net income |
0.56 | 0.58 | 0.48 | 0.62 | |
Capex/Depreciation |
(0.26) | (0.03) | (0.51) | (0.16) | |
Interest Coverage |
(11.99) | (6.06) | (5.78) | (4.43) | |
Research and Development Expense of Revenue |
134.76% | 110.71% | 119.35% | 110.80% | |
Selling, General and Administrative Expense of Revenue |
270.24% | 203.60% | 261.56% | 275.90% | |
Intangible Assets out of Total Assets |
0.04 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
97.63% | 68.51% | 22.39% | 58.60% | |
Graham Net Nets |
0.05 | (0.47) | (0.77) | (1.12) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(328.14%) | (747.93%) | (637.68%) | (766.82%) | |
Free Cash Flow Yield |
(178.04%) | (353.72%) | (334.63%) | (304.62%) | |
Revenue per Share |
5.72 | 5.09 | 4.59 | 2.45 | |
Operating CF per Share |
(14.01) | (9.79) | (11.92) | (6.86) | |
Capex per Share |
(0.77) | (0.08) | (1.32) | (0.29) | |
Free Cash Flow per Share |
(14.78) | (9.87) | (13.23) | (7.15) | |
Cash per Share |
34.16 | 41.42 | 41.59 | 21.10 | |
Shareholders Equity per Share |
41.19 | 19.23 | 14.96 | 3.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
41.19 | 19.23 | 14.96 | 3.94 | |
Free Cash Flow |
(4.70) | (4.25) | (5.49) | (5.15) | |
Working Capital |
14.20 | 20.58 | 18.26 | 15.94 | |
Capital Expenditures |
(0.25) | (0.03) | (0.55) | (0.21) | |
Net Current Asset Value |
0.72 | (2.92) | (4.41) | (7.20) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.14 | 0.02 | 0.29 | 0.12 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.72 | 0.90 | 0.90 | 0.97 | |
Average Payables |
1.70 | 2.28 | 2.18 | 1.85 | |
Average Inventory |
2.38 | 2.07 | 1.91 | 1.86 | |
Average Assets |
41.99 | 35.46 | 32.72 | 30.50 | |
Average Common Equity |
21.19 | 13.33 | 10.28 | 6.62 |
Columns are period end dates · fundamentals updated 28 Sep 2026